PerkinElmer produces and distributes ultra-pure Yttrium-90 radionuclide, which is extracted from Strontium-90 using a patented process licensed exclusively to PerkinElmer. Every lot of Yttrium-90 is quality tested to ensure consistency. Documentation of test results at release, such as the ICP analysis for metals contamination, is provided with each shipment.
Based on its high purity and concentration, NEN® brand Yttrium-90 radionuclide is being combined with various monoclonal antibodies and peptides to create potential "Smart Drugs" which specifically target a number of cancers. This promising therapeutic application is currently being investigated in clinical trials for treating cancers such as ovarian, lung, breast, colon, prostate, brain, and non-Hodgkin's lymphoma. Through its worldwide distribution capabilities, PerkinElmer can assure delivery of this radioisotope to many areas of the world soon after production.